Market Place
Sourcing Support
Akari Therapeutics Appoints Torsten Hombeck as CFO
16 Dec 2024 //
GLOBENEWSWIRE
Akari Therapeutics Regains Full Nasdaq Compliance
19 Nov 2024 //
GLOBENEWSWIRE
Akari Completes Merger with Peak Bio Successfully
14 Nov 2024 //
GLOBENEWSWIRE
Akari Therapeutics Shareholder Approval for Peak Bio Merger
08 Nov 2024 //
GLOBENEWSWIRE
Akari Therapeutics Announces Effectiveness of Form S-4 and On Nov 7
15 Oct 2024 //
GLOBENEWSWIRE
Rob Bazemore Joins Akari Therapeutics Board of Directors
17 Sep 2024 //
GLOBENEWSWIRE
Akari Therapeutics Receives Positive FDA Feedback On PAS-Nomacopan
19 Aug 2024 //
GLOBENEWSWIRE
Akari Therapeutics Reports Q2 2024 Financial Results And Highlights
19 Aug 2024 //
GLOBENEWSWIRE
Akari Therapeutics: Interim CEO Contract Aligns With Shareholders
05 Jun 2024 //
GLOBENEWSWIRE
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
04 Jun 2024 //
GLOBENEWSWIRE
Akari Therapeutics Reports Q1 2024 Financials, Highlights
16 May 2024 //
GLOBENEWSWIRE
Akari, Peak Bio Plan For Post-Merger Pipeline Prioritization
01 May 2024 //
GLOBENEWSWIRE
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
01 May 2024 //
GLOBENEWSWIRE
Akari To Present PAS-Nomacopan ERG Data At ARVO 2024
15 Apr 2024 //
GLOBENEWSWIRE
Akari Reports Full-Year 2023 Financial Results and Recent Highlights
01 Apr 2024 //
GLOBENEWSWIRE
Akari Therapeutics and Peak Bio Announce Definitive Agreement
05 Mar 2024 //
GLOBENEWSWIRE
Akari Therapeutics to Present at Biotech Showcase 2024
14 Dec 2023 //
GLOBENEWSWIRE
Akari Presents Poster on Progress in Development of PAS-Nomacopan
16 Nov 2023 //
GLOBENEWSWIRE
Akari to Present a Poster on Development of Long-Acting PAS-Nomacopan
06 Nov 2023 //
GLOBENEWSWIRE
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
29 Sep 2023 //
GLOBENEWSWIRE
Akari Therapeutics to Present at Emerging Growth Conference
27 Sep 2023 //
GLOBENEWSWIRE
Akari Therapeutics Announces $2 Million Private Placement Financing
21 Sep 2023 //
GLOBENEWSWIRE
Akari Therapeutics to Host Key Opinion Leader Webinar on HSCT-TMA
19 Sep 2023 //
GLOBENEWSWIRE
Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
05 Sep 2023 //
GLOBENEWSWIRE
Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office
18 Aug 2023 //
GLOBENEWSWIRE
Akari Announces Appointment of Beth-Anne Lang as Senior Vice President
02 Aug 2023 //
GLOBENEWSWIRE
Akari Therapeutics Names Beth-Anne Lang Senior VP of Regulatory Affairs
02 Aug 2023 //
CONTRACT PHARMA
Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the EC
27 Jul 2023 //
GLOBENEWSWIRE
Akari Therapeutics Appoints Wendy DiCicco as Interim Chief Financial Officer
19 Jul 2023 //
GLOBENEWSWIRE
Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric
13 Jul 2023 //
GLOBENEWSWIRE
Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan
11 Jul 2023 //
GLOBENEWSWIRE
Akari Receives +ve Opinion on ODD from the EMA for Nomacopan
06 Jul 2023 //
GLOBENEWSWIRE
Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors
05 Jul 2023 //
GLOBENEWSWIRE
Akari Therapeutics to Participate in A.G.P. Virtual Healthcare Conference
16 May 2023 //
GLOBENEWSWIRE
Akari Therapeutics Reports Full-Year 2022Â Financial Results and Highlights
01 May 2023 //
GLOBENEWSWIRE
Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid
25 Apr 2023 //
GLOBENEWSWIRE
Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy
14 Apr 2023 //
GLOBENEWSWIRE
Akari Therapeutics to Attend ARVO 2023
11 Apr 2023 //
GLOBENEWSWIRE
Akari Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan
03 Apr 2023 //
GLOBENEWSWIRE
Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering
30 Mar 2023 //
GLOBENEWSWIRE
Poland and URPL and MHRA Approve Use of Nomacopan
29 Mar 2023 //
GLOBENEWSWIRE
Akari Announces Presentation of Study from PIII Part A Trial of Nomacopan
21 Feb 2023 //
GLOBENEWSWIRE
Akari Announces Progress Toward IND on PAS-Nomacopan for GA
15 Feb 2023 //
GLOBENEWSWIRE
Akari Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan
13 Feb 2023 //
GLOBENEWSWIRE
Akari Therapeutics to Present at Biotech Showcase 2023
04 Jan 2023 //
GLOBENEWSWIRE
Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic
01 Dec 2022 //
GLOBENEWSWIRE
Akari Therapeutics to Participate in the Ophthalmology Day at BTIG
22 Nov 2022 //
GLOBENEWSWIRE
Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan
10 Nov 2022 //
GLOBENEWSWIRE
Akari Therapeutics Appoints John Neylan as EVP, CMO
08 Nov 2022 //
GLOBENEWSWIRE
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
28 Oct 2022 //
GLOBENEWSWIRE
Akari Therapeutics Reports Second Quarter 2022 Financial Results
27 Sep 2022 //
GLOBENEWSWIRE
Akari Therapeutics Announces $12.75 Million Registered Direct Offering
12 Sep 2022 //
GLOBENEWSWIRE
Akari Therapeutics Narrows Pipeline Focus
01 Aug 2022 //
GLOBENEWSWIRE
Akari Tx Announces +ve Results from Recent PC Studies of PASylated Nomacopan
28 Jul 2022 //
GLOBENEWSWIRE
Akari Therapeutics Reports First Quarter 2022 Financial Results
20 Jul 2022 //
BIOSPACE
Akari Tx`s First Patient to Complete Course in PIII Part A Trial of Nomacopan
07 Jul 2022 //
GLOBENEWSWIRE
Akari Appoints Accomplished Biotech Executive Melissa Bradford-Klug as COO
13 Jun 2022 //
GLOBENEWSWIRE
Akari Therapeutics Presents Results from CASCADE, CORONET Studies in COVID-19
19 May 2022 //
GLOBENEWSWIRE
Akari Therapeutics Reports Full Year 2021 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Akari Tx to Present Results from Compassionate Use of Nomacopan for COVID-19
11 May 2022 //
GLOBENEWSWIRE
